Control of HIV replication through CD4+ and CD8+ T cells might be possible, but the functional and phenotypic characteristics of such cells are not defined. Among cytokines produced by T cells, CCR5 ligands, including macrophage inflammatory protein-1 beta (MIP-1β), compete for the CCR5 coreceptor with HIV, promoting CCR5 internalization and decreasing its availability for virus binding. Interferon (IFN)-γ also has some antiviral activity and has been used as a read-out for T cell immunogenicity. We used cultured ELISpot assays to compare the relative contribution of MIP-1β and IFN-γ to HIV-specific responses. The magnitude of responses was 1.36 times higher for MIP-1β compared to IFN-γ. The breadth of the MIP-1β response (45.41%) was significantly higher than IFN-γ (36.88%), with considerable overlap between the peptide pools that stimulated both MIP-1β and IFN-γ production. Subtype A and D cross-reactive responses were observed both at stimulation and test level, but MIP-1β and IFN-γ responses displayed different effect patterns. We conclude that the MIP-1β ELISpot would be a useful complement to the evaluation of the immunogenicity of HIV vaccines and the activity of adjuvants.
Get full access to this article
View all access options for this article.
References
1.
BurgersWA, RiouC, MlotshwaM, et al.: Association of HIV-specific and total CD8+ T memory phenotypes in subtype C HIV-1 infection with viral set point. J Immunol, 2009; 182(8):4751–4761.
2.
BuchbinderSP, MehrotraDV, DuerrA, et al.: Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet, 2008; 372(9653):1881–1893.
3.
AddoMM, YuXG, RathodA, et al.: Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol, 2003; 77(3):2081–2092.
4.
SekalyRP: The failed HIV Merck vaccine study: A step back or a launching point for future vaccine development?. J Exp Med, 2008; 205(1):7–12.
5.
GoepfertPA, BansalA, EdwardsBH, et al.: A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon. J Virol, 2000; 74(21):10249–10255.
6.
RichmondM, McKinnonLR, KiazykSA, et al.: Epitope mapping of HIV-specific CD8+ T cell responses by multiple immunological readouts reveals distinct specificities defined by function. J Virol, 2011; 85(3):1275–1286.
7.
MurphyPM, BaggioliniM, CharoIF, et al.: International Union of Pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev, 2000; 52(1):145–176.
8.
RichmondA and FanG-H: Chemokine receptors. In: Encyclopedia of Biological Chemistry (LennarzWJ, LaneMD, eds.). Elsevier, Academic Press, San Diego, CA, 2004, Vol. 1, pp. 413–418.
9.
AmellaCA, SherryB, SheppDH, and SchmidtmayerovaH: Macrophage inflammatory protein 1alpha inhibits postentry steps of human immunodeficiency virus type 1 infection via suppression of intracellular cyclic AMP. J Virol, 2005; 79(9):5625–5631.
10.
CasazzaJP, BrenchleyJM, HillBJ, et al.: Autocrine production of beta-chemokines protects CMV-specific CD4 T cells from HIV infection. PLoS Pathog, 2009; 5(10):e1000646.
11.
HladikF, SakchalathornP, BallweberL, et al.: Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity, 2007; 26(2):257–270.
12.
KeeleBF, GiorgiEE, Salazar-GonzalezJF, et al.: Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA, 2008; 105(21):7552–7557.
13.
MargolisL and ShattockR: Selective transmission of CCR5-utilizing HIV-1: The 'gatekeeper' problem resolved?. Nat Rev Microbiol, 2006; 4(4):312–317.
14.
FreelSA, LamoreauxL, ChattopadhyayPK, et al.: Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination. J Virol, 2010; 84(10):4998–5006.
15.
FerrariG, KorberB, GoonetillekeN, et al.: Relationship between functional profile of HIV-1 specific CD8 T cells and epitope variability with the selection of escape mutants in acute HIV-1 infection. PLoS Pathog, 2011; 7(2):e1001273.
16.
JinX, BauerDE, TuttletonSE, et al.: Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med, 1999; 189(6):991–998.
17.
SchmitzJE, KurodaMJ, SantraS, et al.: Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science, 1999; 283(5403):857–860.
18.
PriceDA, GoulderPJ, KlenermanP, et al.: Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci USA, 1997; 94(5):1890–1895.
19.
KoupRA, SafritJT, CaoY, et al.: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol, 1994; 68(7):4650–4655.
20.
Borrow PH.L, ewickiX.Wei, et al.: Antiviral pressure exerted by human immunodeficiency virus type 1 specific cytotoxic T-lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med, 1997; 3:205–211.
21.
O'ConnorDH, AllenTM, VogelTU, et al.: Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat Med, 2002; 8(5):493–499.
22.
JonesNA, WeiX, FlowerDR, et al.: Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. J Exp Med, 2004; 200(10):1243–1256.
23.
PriceDA, WestSM, BettsMR, et al.: T cell receptor recognition motifs govern immune escape patterns in acute SIV infection. Immunity, 2004; 21(6):793–803.
24.
GoonetillekeN, LiuMK, Salazar-GonzalezJF, et al.: The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med, 2009; 206(6):1253–1272.
25.
DembekCJ, KutscherS, HeltaiS, et al.: Nef-specific CD45RA+ CD8+ T cells secreting MIP-1beta but not IFN-gamma are associated with nonprogressive HIV-1 infection. AIDS Res Ther, 2010; 7:20.
26.
CocchiF, DeVicoAL, YarchoanR, et al.: Higher macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels from CD8+ T cells are associated with asymptomatic HIV-1 infection. Proc Natl Acad Sci USA, 2000; 97(25):13812–13817.
27.
HandenJS, and RosenbergHF: Suppression of HIV-1 transcription by beta-chemokines RANTES, MIP1-alpha, and MIP-1beta is not mediated by the NFAT-1 enhancer element. FEBS Lett, 1997; 410(2–3):301–302.
28.
CocchiF, DeVicoAL, Garzino-DemoA, et al.: Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science, 1995; 270(5243):1811–1815.
29.
BritoA, AlmeidaA, GonsalezCR, et al.: Successful HAART is associated with high B-chemokine levels in chronic HIV type 1-infected patients. AIDS Res Hum Retroviruses, 2007; 23(7):906–912.
30.
FiebigEW, WrightDJ, RawalBD, et al.: Dynamics of HIV viremia and antibody seroconversion in plasma donors: Implications for diagnosis and staging of primary HIV infection. AIDS, 2003; 17(13):1871–1879.
31.
RoedererM and KoupRA: Optimized determination of T cell epitope responses. J Immunol Methods, 2003; 274(1–2):221–228.
32.
CurrierJR, KutaEG, TurkE, et al.: A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods, 2002; 260(1–2):157–172.
33.
WinstoneN, Guimaraes-WalkerA, RobertsJ, et al.: Increased detection of proliferating, polyfunctional, HIV-1-specific T cells in DNA-modified vaccinia virus Ankara-vaccinated human volunteers by cultured IFN-gamma ELISPOT assay. Eur J Immunol, 2009; 39(4):975–985.
34.
GoonetillekeN, MooreS, DallyL, et al.: Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J Virol, 2006; 80(10):4717–4728.
35.
YueFY, KovacsCM, DimayugaRC, et al.: Preferential apoptosis of HIV-1-specific CD4+ T cells. J Immunol, 2005; 174(4):2196–2204.
36.
DoitshG, GallowayNL, GengX, et al.: Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature, 2014; 505(7484):509–514.
37.
DayCL, KaufmannDE, KiepielaP, et al.: PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature, 2006; 443(7109):350–354.
38.
HarariA, RizzardiGP, EllefsenK, et al.: Analysis of HIV-1- and CMV-specific memory CD4 T-cell responses during primary and chronic infection. Blood, 2002; 100(4):1381–1387.
39.
DouekDC, BrenchleyJM, BettsMR, et al.: HIV preferentially infects HIV-specific CD4+ T cells. Nature, 2002; 417(6884):95–98.
40.
GeldmacherC, CurrierJR, GerhardtM, et al.: In a mixed subtype epidemic, the HIV-1 Gag-specific T-cell response is biased towards the infecting subtype. AIDS (London, England), 2007; 21(2):135–143.
41.
MugabaS, NakibonekaR, NanyonjoM, et al.: Group M consensus Gag and Nef peptides are as efficient at detecting clade A1 and D cross-subtype T-cell functions as subtype-specific consensus peptides. Vaccine, 2014; 32(30):3787–3795.
42.
BarugahareB, BakerC, K'AluochO, et al.: Human immunodeficiency virus-specific responses in adult Ugandans: Patterns of cross-clade recognition. J Virol, 2005; 79(7):4132–4139.
43.
GiorgiEE, BalachandranH, MuldoonM, et al.: Cross-reactive potential of human T-lymphocyte responses in HIV-1 infection. Vaccine, 2014; 32(31):3995–4000.
44.
PalaP, SerwangaJ, WateraC, et al.: Quantitative and qualitative differences in the T cell response to HIV in uninfected Ugandans exposed or unexposed to HIV-infected partners. J Virol, 2013; 87(16):9053–9063.
45.
SuLF and DavisMM: Antiviral memory phenotype T cells in unexposed adults. Immunol Rev, 2013; 255(1):95–109.
46.
SuLF, KiddBA, HanA, et al.: Virus-specific CD4+ memory-phenotype T cells are abundant in unexposed adults. Immunity, 2013; 38(2):373–383.
47.
CampionSL, BrodieTM, FischerW, et al.: Proteome-wide analysis of HIV-specific naive and memory CD4+ T cells in unexposed blood donors. J Exp Med, 2014; 211(7):1273–1280.
48.
NovitskyV, GilbertP, PeterT, et al.: Association between virus-specific T-cell responses and plasma viral load in human immunodeficiency virus type 1 subtype C infection. J Virol, 2003; 77(2):882–890.
49.
KiepielaP, NgumbelaK, ThobakgaleC, et al.: CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med, 2007; 13(1):46–53.
50.
GeldmacherC, CurrierJR, HerrmannE, et al.: CD8 T-cell recognition of multiple epitopes within specific Gag regions is associated with maintenance of a low steady-state viremia in human immunodeficiency virus type 1-seropositive patients. J Virol, 2007; 81(5):2440–2448.
51.
MasemolaA, MashishiT, KhouryG, et al.: Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: Correlation with viral load. J Virol, 2004; 78(7):3233–3243.
52.
StreeckH, LichterfeldM, AlterG, et al.: Recognition of a defined region within p24 gag by CD8+ T cells during primary human immunodeficiency virus type 1 infection in individuals expressing protective HLA class I alleles. J Virol, 2007; 81(14):7725–7731.
53.
ZunigaR, LucchettiA, GalvanP, et al.: Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. J Virol, 2006; 80(6):3122–3125.
54.
RiouC, BurgersWA, MlisanaK, et al.: Differential impact of magnitude, polyfunctional capacity, and specificity of HIV-specific CD8+ T cell responses on HIV set point. J Virol, 2014; 88(3):1819–1824.
55.
KarlssonAC, MartinJN, YoungerSR, et al.: Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. J Immunol Methods, 2003; 283(1–2):141–153.
Rerks-NgarmS, PitisuttithumP, NitayaphanS, et al.: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med, 2009; 361(23):2209–2220.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
